Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

Siemens Healthineers is debuting its first fully sealed 1.5 Tesla MRI scanner, designed to dramatically reduce its use of ...

After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset ...

Oncternal could receive up to $65 million in milestones if the programs are successful. Regulatory events account for $40 ...

Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences ...

Medtronic and Philips have re-upped their long-running partnership focused on bundling vital sign sensors together with ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Shanghai and San Francisco Bay Area-based HanchorBio has already taken HCB101, an engineered SIRPα-IgG4 Fc fusion protein, into phase 2 trials for solid tumors and hematologic malignancies, including ...

Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...